Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone — RROPE

Prostate Cancer Metastatic to Bone Clinical Trial

Official title:
A Phase 2 Study of Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

Status Completed

Clinical Trial Summary

This is a phase IIa, open label, single arm, and prospective study of hormone therapy-naïve men with oligometastatic prostate cancer to the bone. The study will test if treating the primary tumor sites and 5 or fewer sites of bone-only metastasis with external beam radiation with concomitant systemic Radium-223 will reduce the utilization of androgen deprivation therapy, improve QOL and improve OS over a the comparator cohort of SWOG intermittent ADT historic cohort.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Prostate Cancer Metastatic to Bone
Prostatic Neoplasms

Clinical Trial Details

NCT number	NCT03304418
Study type	Interventional
Source	University of Utah
Contact
Status	Completed
Phase	Phase 2
Start date	February 27, 2018
Completion date	August 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06430411` - Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
Active, not recruiting	`NCT03458559` - Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy	Phase 3
Withdrawn	`NCT04483414` - 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer	Phase 2
Recruiting	`NCT03134261` - Diagnostic Imaging of Bone Metastases in Prostate Cancer Patients	N/A